ReviewMedicine2026
Clinical analysis of nine cases of uterine intravenous leiomyomatosis and review of the literature.
Review in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Intravenous leiomyomatosis (IVL) is a rare and special type variant of leiomyoma characterized by intravascular proliferation of benign smooth muscle cells extending beyond the uterus into the heart and even to the pulmonary arteries through a variety of ways. Owing to its rare occurrence and lacking of obvious symptoms, early diagnosis is very difficult. Complete excision of tumors is vital for a favorable prognosis. There is no consensus about the operative drug-assisted treatment to reduce the risk of recurrence. Pathogenesis of IVL is not clear, and chromosomal and genetic changes may accelerated the development of IVL. Herein, we report 9 patients with early stage IVL. Nine patients were admitted to the hospital with different symptoms for surgical treatment, and postoperative pathology was suggestive of intravascular smooth muscle tumor. Close follow-up of the patient post-operatively revealed that hysterectomy and bilateral adnexectomy could be chosen when the mass was limited to the uterus or pelvic cavity, and for patients with fertility requirements, myomectomy might also be feasible. About hormonal or the other adjuvant therapies after operation, there are still controversies, and further studies are needed to verify these findings. We retrospectively analyzed the clinical data of the patients and explored their clinical features, treatment and prognosis, aiming to improve the understanding of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.